Company intelligence / Profile preview

Genuv

Jung-gu, Seoul, South Koreagenuv.com ↗

Ownership: Private
Employees: ~50
Development stage: Clinical

Overview

Genuv’s lead candidate, SNR161/SNR1611NF, is in Phase I/IIa clinical trials for ALS and has shown restoration of CNS function in preclinical models of ALS and Alzheimer’s. The company uses its ATRIVIEW® platform to identify neuroprotective and neurogenerative compounds. Additional programs are at discovery or preclinical stages targeting solid tumors with novel antibodies.[5][8]

Therapeutic areas: OncologyImmunologyNeurology
Modalities: Small moleculesMonoclonal antibodies (mAbs)Fusion proteins
Industry: Biotech

Drug pipeline

6 assets

GNUV201

Preclinical

5 more assets in the full pipeline.

Request access →

Partnerships

– Aiforia Plc. – AI/deep learning technology partnership to enhance ATRIVIEW® drug discovery speed and precision[5]– No major pharma licensing deals disclosed as of now.

Beyond the preview

Go deeper on Genuv.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Genuv.

Explore the full profile